Osteoporosis researchers do not suffer from a lack of potential drug targets—so one challenge is to decide which ones to focus on. Yongwon Choi, Matthew C. Walsh and Joseph R. Arron now examine several molecules involved in bone biology and assess their prospects. In a second commentary, Cliff Rosen analyzes findings that serotonin, derived from the gut, regulates bone formation. The findings not only could lead to new drug targets, they also could help explain clinical data that serotonin reuptake inhibitors—widely prescribed as antidepressants—weaken bones.
- Yongwon Choi
- Matthew C Walsh
- Joseph R Arron